EMT/MET Plasticity in Cancer and Go-or-Grow Decisions in Quiescence: the Two Sides of the Same Coin?

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2023 May 31

PMID 37259089

Authors

Azamat Akhmetkaliyev

Noura Alibrahim

Darya Shafiee

Eugene Tulchinsky

Affiliations

Soon will be listed here.

Abstract

Epithelial mesenchymal transition (EMT) and mesenchymal epithelial transition (MET) are genetic determinants of cellular plasticity. These programs operate in physiological (embryonic development, wound healing) and pathological (organ fibrosis, cancer) conditions. In cancer, EMT and MET interfere with various signalling pathways at different levels. This results in gross alterations in the gene expression programs, which affect most, if not all hallmarks of cancer, such as response to proliferative and death-inducing signals, tumorigenicity, and cell stemness. EMT in cancer cells involves large scale reorganisation of the cytoskeleton, loss of epithelial integrity, and gain of mesenchymal traits, such as mesenchymal type of cell migration. In this regard, EMT/MET plasticity is highly relevant to the Go-or-Grow concept, which postulates the dichotomous relationship between cell motility and proliferation. The Go-or-Grow decisions are critically important in the processes in which EMT/MET plasticity takes the central stage, mobilisation of stem cells during wound healing, cancer relapse, and metastasis. Here we outline the maintenance of quiescence in stem cell and metastatic niches, focusing on the implication of EMT/MET regulatory networks in Go-or-Grow switches. In particular, we discuss the analogy between cells residing in hybrid quasi-mesenchymal states and G, an intermediate phase allowing quiescent stem cells to enter the cell cycle rapidly.

Citing Articles

Phospholipase C Beta 2 as a Key Regulator of Tumor Progression and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Renal Cell Carcinoma.

Wang S, Xie D, Yue H, Li G, Jiang B, Gao Y Biomedicines. 2025; 13(2).

PMID: 40002717 PMC: 11853330. DOI: 10.3390/biomedicines13020304.

Divergent PTEN-p53 interaction upon DNA damage in a human thyroid organoid model with germline PTEN mutations.

Venegas J, Onur O, Kang S, Hitomi M, Eng C Endocr Relat Cancer. 2025; 32(4).

PMID: 39970536 PMC: 11906015. DOI: 10.1530/ERC-24-0216.

Effect of Cumulative Zinc Doses on Papillary Muscle Contractions and the Zinc Finger Protein ZEB1.

Akgun-Unal N, Akgun-Unal N, Ustun A, Bayirli S, Unal O, Mogulkoc R Biol Trace Elem Res. 2025; .

PMID: 39964653 DOI: 10.1007/s12011-025-04550-z.

SHCBP1 is a novel regulator of PLK1 phosphorylation and promotes prostate cancer bone metastasis.

Tang C, Peng S, Chen Y, Cheng B, Li S, Zhou J MedComm (2020). 2025; 6(2):e70082.

PMID: 39949984 PMC: 11822462. DOI: 10.1002/mco2.70082.

Specific modulation of 28S_Um2402 rRNA 2'--ribose methylation as a novel epitranscriptomic marker of ZEB1-induced epithelial-mesenchymal transition in different mammary cell contexts.

Morin C, Paraqindes H, Nguyen Van Long F, Isaac C, Thomas E, Pedri D NAR Cancer. 2025; 7(1):zcaf001.

PMID: 39877292 PMC: 11773364. DOI: 10.1093/narcan/zcaf001.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Risson E, Nobre A, Maguer-Satta V, Aguirre-Ghiso J . The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2021; 1(7):672-680. PMC: 7929485. DOI: 10.1038/s43018-020-0088-5. View

Tong Z, Cai M, Wang X, Kong L, Mai S, Liu Y . EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2011; 31(5):583-94. DOI: 10.1038/onc.2011.254. View

Shi Y, Sawada J, Sui G, Affar E, Whetstine J, Lan F . Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature. 2003; 422(6933):735-8. DOI: 10.1038/nature01550. View

Visal T, den Hollander P, Cristofanilli M, Mani S . Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?. Br J Cancer. 2022; 127(2):173-184. PMC: 9296521. DOI: 10.1038/s41416-022-01768-9. View

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

Goossens S, Vandamme N, Van Vlierberghe P, Berx G . EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017; 1868(2):584-591. DOI: 10.1016/j.bbcan.2017.06.006. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Jeannot P, Nowosad A, Perchey R, Callot C, Bennana E, Katsube T . p27 promotes invadopodia turnover and invasion through the regulation of the PAK1/Cortactin pathway. Elife. 2017; 6. PMC: 5388532. DOI: 10.7554/eLife.22207. View

10.

Vincent T, Neve E, Johnson J, Kukalev A, Rojo F, Albanell J . A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009; 11(8):943-50. PMC: 3769970. DOI: 10.1038/ncb1905. View

11.

Chung V, Tan T, Ye J, Huang R, Lai H, Kappei D . The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. Commun Biol. 2019; 2:272. PMC: 6656769. DOI: 10.1038/s42003-019-0506-3. View

12.

Bruneel K, Verstappe J, Vandamme N, Berx G . Intrinsic Balance between ZEB Family Members Is Important for Melanocyte Homeostasis and Melanoma Progression. Cancers (Basel). 2020; 12(8). PMC: 7465899. DOI: 10.3390/cancers12082248. View

13.

Rock J, Onaitis M, Rawlins E, Lu Y, Clark C, Xue Y . Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc Natl Acad Sci U S A. 2009; 106(31):12771-5. PMC: 2714281. DOI: 10.1073/pnas.0906850106. View

14.

Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F . Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56(23):3203-3221.e11. DOI: 10.1016/j.devcel.2021.11.006. View

15.

Auyez A, Sayan A, Kriajevska M, Tulchinsky E . AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew. Cancers (Basel). 2021; 13(19). PMC: 8507788. DOI: 10.3390/cancers13194864. View

16.

Batard P, Monier M, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T . TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. J Cell Sci. 2000; 113 ( Pt 3):383-90. DOI: 10.1242/jcs.113.3.383. View

17.

Ikushima H, Miyazono K . TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010; 10(6):415-24. DOI: 10.1038/nrc2853. View

18.

Tzeng Y, Li H, Kang Y, Chen W, Cheng W, Lai D . Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood. 2010; 117(2):429-39. DOI: 10.1182/blood-2010-01-266833. View

19.

Nguyen H, Xiao L, Deane J, Tan K, Cousins F, Masuda H . N-cadherin identifies human endometrial epithelial progenitor cells by in vitro stem cell assays. Hum Reprod. 2017; 32(11):2254-2268. DOI: 10.1093/humrep/dex289. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View